Acasti Pharma Inc
Change company Symbol lookup
Select an option...
ACST Acasti Pharma Inc
STBX Starbox Group Holdings Ltd
ANCFX American Funds Fundamental Investors® Class A
DFS Discover Financial Services
EJH E-Home Household Service Holdings Ltd
PYXS Pyxis Oncology Inc
FLGC Flora Growth Corp
BAOS Baosheng Media Group Holdings Ltd
CETY Clean Energy Technologies Inc
UEC Uranium Energy Corp

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Value
Based in Canada
Company profile

Acasti Pharma Inc. is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The Company's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The Company's other pipeline products include GTX-102, an oral mucosal spray formulation of betamethasone intended to develop neurological symptoms of A-T, including developing clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine for the treatment of PHN.

Day's Change
-0.0002 (-0.05%)
B/A Size
Day's High
Day's Low

Today's volume of 18,082 shares is on pace to be much lighter than ACST's 10-day average volume of 55,570 shares.


Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.